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Abstract 
B Acute Lymphoblastic leukemia (B‑ALL) with Philadelphia chromosome (Ph′) is a neoplasm of lymphoblast commit‑
ted to the B cell lineage. The clinical presentation of B‑ALL Ph′+ is similar to B‑ALL, but is more common in adults than 
in children. The e1a3 rare variant is produced by the fusion of BCR exon 1 to ABL exon 3. The presence of this translo‑
cation has been associated with good disease outcome for chronic myeloid leukemia in a very small series of only 5 
cases; there is no such evidence for B‑ALL. We report two new cases of B‑ALL Ph+ with the rare e1a3 fusion transcript. 
The e1a3 and e1a2 (p190) transcripts have been reported to have a similar molecular weight and probably a similar 
clinical profile, thus in these cases the presence of e1a3 was associated with extramedullary infiltration and disease 
acceleration.
© 2016 López‑Andrade et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
B Acute Lymphoblastic leukemia (B-ALL) with Phila-
delphia chromosome (Ph′) is a neoplasm of lymphoblast 
committed to the B-cell lineage. The clinical presentation 
of B-ALL Ph′+ is similar to B-ALL, but is more com-
mon in adults than in children and it has a worse prog-
nosis among patients with B-ALL. The tyrosine kinase 
BCR-ABL fusion protein is the product of the Philadel-
phia chromosome, which results from the reciprocal 
translocation t(9;22)(q34;q11) that juxtaposes the c-abl 
oncogene 1 on chromosome 9 with the bcr gene on chro-
mosome 22 generating the BCRABL1 oncogene [1–4]. 
Depending on the location of the breakpoint in BCR, 
several types of BCR-ABL fusion proteins may appear 
[5]. To date, three main breakpoint cluster regions in the 
BCR gene have been reported: the M-bcr region located 
between exons 12 and 16, the m-bcr located between 
exons e2′ and e2 and the u-bcr located in exon 19. The 
three more common variants of BCR-ABL described 
are p210 [more frequent in chronic myeloid leukemia 
(CML)], p190 (more frequent in B-ALL) and p230 (more 
frequent in Chronic Neutrophilic Leukemia (CNL) [6–
8]. The type of rearrangement in CML is related to the 
patient clinical course. Other rare forms such as e1a3, 
b2a3 and e6a2 of BCR-ABL have been described. The 
e1a3 variant is produced by the fusion of BCR exon 1 to 
ABL exon 3. The presence of this translocation has been 
associated with good disease outcome for CML in a very 
small series of only 5 cases [9, 10]; there is no such evi-
dence for ALL. Moreover, we have reported the first e1a3 
case that progressed from CML to a lymphoid blast crisis 
[1]. Thus, the molecular prognosis of these rare variant 
forms is still unclear. We report two new cases of B-ALL 
Ph+ with the rare e1a3 fusion transcript.
Case 1 presentation
The first patient is a 43-year-old male, who consulted our 
center for night sweats and weight loss in the last 3 weeks. He 
had no previous history or records in our center. The physi-
cal examination was normal except for a slight splenomegaly 
and the blood test was compatible with hyperleukocytosis, 
anemia and thrombocytopenia, (leukocytes 136.00  ·  109/L, 
hemoglobin 11.70 g/dl, platelet count 39.70 · 109/L) and 93 % 
of small-medium sized lymphoblast in the Grunwald-Giemsa 
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blood smear. The bone marrow aspirate examination had 
an hypercellular infiltration of 90  % which was confirmed 
by immunophenotype (CD19+, CD10+, CD34+, TdT+, 
DR+, CD79 alfa+, CD20−, cytoplasm IgM negative). 80 % 
of the blast cells also expressed CD33+. A fresh sample 
from the bone marrow aspirate was collected for molecu-
lar and cytogenetic analysis. The assay revealed the pres-
ence of the following karyotype:46,XY,t(9;22)(q34;q11) [2] 
/46,XY,del(9)(p22)t(9;22)(q34;q11) [4] /46,XY,del(9)(p22)
t(9;22)(q34;q11),del(20)(q13) [5] /46,XY [9]. FISH analysis 
confirmed the presence of BCR-ABL1 fusion gene (Fig. 1). 
The patient’s RNA was isolated from the peripheral blood 
and subjected to a two round multiplex reverse transcription 
and polymerase chain reaction (RT-PCR). In order to avoid 
RNA quality and/or handling errors, we included an internal 
positive control in where a 690-bp segment of the ubiqui-
tously expressed transcription factor E2A mRNA was ampli-
fied. The primers and PCR conditions used in the first and 
second round of the nested PCR reaction are described by 
Pallisgaard et al. [11]. We identified an atypical amplification 
band of approximately 100 bp, much smaller than the p190 
(e1a2) fragment. In order to confirm the presence of a BCR-
ABL transcript this band was extracted from the agarose 
gel, purified and then analyzed by DNA sequencing. cDNA 
sequence revealed the presence of the e1a3 variant (Fig. 2). 
The patient started induction treatment with ALL-type 
polychemotherapy and Imatinib, achieving complete 
response by morphology and immunophenotype. How-
ever, the BCR/ABL was still detected by RT-PCR at the 
end of the induction phase. He is ongoing consolidation 
with allogenic stem cell transplantation (SCT) from an 
HLA-identical sibling donor, 7 months after diagnosis.
Case 2 presentation
The second patient is a 65-year-old male who consulted for 
pain in the right leg and a history of recurrent periodontal 
infections in the last month. An eco-doppler confirmed a 
thrombophlebitis and the blood test found hyperleukocy-
tosis and anemia (leukocytes 223.00  · 109/L, Hemoglobin 
11.60 g/dl, platelet count 118 · 109/L) and the presence of 
80 % lymphoblasts in the Grunwald-Giemsa blood smear. 
The bone marrow aspirate found an infiltration of 25  % 
lymphoblast which was confirmed by immunophenotype 
(CD19+, CD34+, DR+, CD10+, CD22+, low intensity 
CD20−, TdT+, cytoplasmatic IgM negative, CD33+). The 
karyotype was 46,XY,t(9;22)(q34;q11) [20]. FISH analysis 
confirmed the presence of BCR-ABL1 fusion gene (Fig. 1). 
The patient’s RNA was isolated from the peripheral blood. 
We identified an atypical e1a3 variant after a two round 
PCR amplification by DNA sequencing (Fig. 2).
The patient started induction treatment and Imatinib. 
The bone marrow aspirate on day 34 confirmed pro-
gressive disease with 30 % blast and persistence of BCR/
ABL. After a second line of intensive ALL-type induction 
therapy the patient finally died due to toxicity (gastroin-
testinal bleeding). No SCT had been planned due to age 
and unfit status. It is noteworthy that the blood counts in 
a regular check-up 4 months before the diagnosis had a 
slight leukocytosis that was not studied.
Discussion
Overall only a few cases with the e1a3 BCRABL fusion pro-
teins have been reported. This rare variant has mostly been 
described with an indolent clinical course in the setting of 
CML and its role in B-ALL is still unclear. We report two 
new cases of e1a3 Ph+ ALL patients in where we highlight 
the finding of the myeloid CD33+  marker expression by 
immunophenotype (biphenotypic and bilineal blast popu-
lation were discarded by EGIL classification). This means 
that both cases could be defined as acute lymphoblastic 
leukemia with aberrant myeloid markers (ALL My+). We 
previously speculated that B-ALL e1a3 cases could repre-
sent CML in lymphoid blast crisis that underwent an under 
diagnosed chronic phase. In one of our cases we do not 
have any blood counts prior to the B-ALL diagnosis. How-
ever the other presented a non-evaluated leukocytosis in 
the blood count available before diagnosis.
A review of the bibliography of reported cases of B-ALL 
with the e1a3 fusion protein, using the terms “B-Acute 
lymphoblastic leukemia” and “e1a3” found a total of 18 
cases plus the 2 being reported in this manuscript. The 
rare e1a3 translocation was also previously reported in 
the literature in 6 patients with CML in chronic phase. 
Furthermore, we described for the first time a patient 
with CML diagnosis that after 5  months of Imatinib 
treatment evolved to lymphoid blast crisis [1]. Table  1 
shows all ALL cases with the e1a3 fusion protein previ-
ously reported as well as our 2 additional patients. The 
(See figure on next page.) 
Fig. 1 Cytogenetic, FISH and Immunophenotype results 1a G‑banded karyotype from the sideline 46,XY,del(9)(p22)t(9;22)(q34;q11),del(20)(q13). 
1b Metaphase FISH image showing BCR‑ABL1 fusion gene at minor breakpoint BCR. Green BCR, red ABL1. 1c G‑banded karyotype showing t(9;22)
(q34;q11) as a sole chromosome alteration. 1d Metaphase FISH image showing BCR‑ABL1 fusion gene at minor breakpoint BCR. LSI BCR/ABL1 dual 
color translocation probe (Abbott) was used. Green: BCR, Red: ABL1. 2a Immunophenotype of ALL with atypical e1a3 translocation. Presence of 
90 % of blasts with lymphoblastic phenotype B: CD19+, CD10+, CD34+, DR+, CD20+, CD22−, CD33+, cytoplasmic IgM negative and positive 
alpha CD79. 2b Immunophenotype of ALL with atypical e1a3 translocation. Presence of 80 % of blasts with lymphoblastic phenotype B: CD19+, 
CD10+, CD34+, DR+, CD20+, CD22−, cytoplasmic IgM negative, positive alpha CD79 and dim expression of CD33
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information provided by these reports shows that these 
cases were aggressive with 44 % of cases being refractory 
or relapsing after therapy and 55 % having already died at 
last follow-up.
The review of our cases and the other previously 
reported shows an aggressive disease similar to other 
Ph+ ALL. More data is needed in order to clearly define 
the real prognosis of B-ALL cases with e1a3 translocation 
Fig. 2 DNA sequencing of BCR‑ABL e1a3 atypical amplification band purified from both patients
Table 1 Clinical characteristics, therapy and  outcome of  ALL cases reported with  e1a3 fusion protein compared 
with those presented in this manuscript
B-ALL B‑lymphoblastic leukemia/lymphoma, CML chronic myeloid leukemia, Allo SCT allogeneic hematopoietic stem cell transplantation, CCR clinical complete 
remission, TKI tyrosine kinase inhibitor, NA not available
# Age Leukocite count at Dx BM infiltration TKI SCT Status Response References
1 65 years 223 × 103 25 % Imatinib – Dead Refractory Current
2 43 years 133 × 103 90 % Imatinib AlloSCT (ongoing) Alive CR Current
3 76 years 7000 85 % Dasatinib – Alive CR Sonu [12]
4 Unk 5.530 × 109/L 90 % Imatinib Allo SCT Alive CR Shin 13]
5 Unk 24.36 × 109/L 80 % Imatinib – Dead Not achieved Shin [13]
6 80 years 94 % at blast crisis Imatinib – Dead CML transformed to B‑ALL Martinez‑Serra [1]
7 62 years NA NA Imatinib – Dead relapse Langabeer [14]
8 25 years NA NA – 2d AlloSCT Dead Relapse/VOD Fujisawa [15]
9 62 years 10 NA – Autologous Dead relapse Burmeister [16]
10 64 years 1.8 NA – – Dead relapse Burmeister [16]
11 31 years 31 NA Imatinib Allo SCT Alive CCR Burmeister [16]
12 61years 14 NA Imatinib – Alive CCR Burmeister [16]
13 48 years 62 NA – – Dead Relapse Burmeister [16]
14 37 years 70 NA Imatinib AlloSCT Alive CCR Burmeister [16]
15 45 years 5 NA Imatinib AlloSCT Alive CCR Burmeister [16]
16 29 years 40 NA Imatinib AlloSCT Alive CCR Burmeister [16]
17 NA NA NA NA NA NA NA Wilson [17]
18 1 year NA NA NA NA Dead NA Iwata [18]
19 39 years NA NA NA NA Dead NA Soakerman [19]
20 NA NA NA NA NA NA NA Chen [20]
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and state if these patients could benefit from TKI or 
other approaches such as Allo SCT at consolidation. The 
e1a3 and e1a2 (p190) transcripts have been reported to 
have a similar molecular weight and probably a simi-
lar clinical profile, meaning that e1a3 could be associ-
ated with the presence of extramedullary infiltration and 
disease acceleration, with both patients (one achieving 
CR and one with PD) having persistence of e1a3 at the 
molecular level after induction treatment. Moreover, it is 
important that our reference laboratory is able to detect 
the rare e1a3 BCR-ABL avoiding false e1a3 negatives, in 
both ALL and CML.
Conclusion
We report 2 new cases of B-ALL with the rare e1a3 BCR-
ABL fusion protein. At the moment the particular prog-
nostic significance of e1a3 remains undetermined, but 
considering our cases and the other previously described, 
it seems that a clinical management with protocols of 
Ph+ ALL should be offered to eligible patients. The study 
of the clinical significance of these variants at diagnosis 
and follow up, is important to define if these patients 
have a higher risk of relapse or progressive disease in 
comparison to other BCR/ABL transcripts and could 
benefit from SCT.
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